ADXS-HPV: Phase II data

Data from 40 patients in cohort 1 of a single-blind, dose-escalation, U.S. Phase II trial showed that 52% of CIN 2/3 lesions regressed to CIN 1 or normal in patients receiving low-dose ADXS-HPV vs. 40...